Abstract:Cyclin-dependent kinases (CDKs) constitute a vital family of protein-serine kinases, pivotal in regulating various cellular processes such as the cell cycle, metabolism, proteolysis, and neural functions. Dysregulation or overexpression of CDK kinases is directly linked to the development of cancer. However, the currently approved CDK inhibitors by the US FDA, such as palbociclib, ribociclib, Trilaciclib, Abemaciclib, etc., although effective, exhibit limited specificity and often lead to undesirable adverse effects. First and second-generation CDK inhibitors have not gained significant clinical interaction due to their high toxicity and lack of specificity. To address these challenges, a combined approach is being employed in the quest for newer CDK inhibitors aimed at mitigating toxicity and side effects associated with CDKIs. The discovery of therapeutic agents selectively targeting tumorous cells, such as CDK inhibitors, has demonstrated promise in treating various cancers, including breast cancer. Extensive literature reviews have facilitated the development of novel CDK inhibitors by combining medicinally preferred pyrimidine derivatives with other heterocyclic rings. Pyrimidine derivatives substituted with pyrazole, imidazole, benzamide, benzene sulfonamide, indole carbohydrazide, and other privileged heterocyclic rings have shown encouraging efficacy in inhibiting cyclin-dependent kinase activity. This review provides comprehensive data, including structure-activity relationship (SAR), anticancer activity, and kinetics studies of potent compounds. Additionally, molecular docking studies with compounds under clinical trial and patents filed on pyrimidine based CDK inhibitors in cancer treatment are included. This review serves as a valuable resource for further development of CDK kinase inhibitors for cancer treatment, offering insights into their efficacy, specificity, and potential clinical applications.

A Patent Review of Cyclin-Dependent Kinase 7 (CDK7) Inhibitors (2018-2022)

Recent Progress in Development of Cyclin-Dependent Kinase 7 Inhibitors for Cancer Therapy

Targeting CDK7 in oncology: The avenue forward.

Recent advances in the development of cyclin-dependent kinase 7 inhibitors

Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019)

A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

A Patent Review of Selective CDK9 Inhibitors in Treating Cancer

CDK7 in Breast Cancer: Mechanisms of Action and Therapeutic Potential.

Cyclin Dependent Kinase 1 Inhibitors: a Review of Recent Progress.

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

A Patent and Literature Review of CDK12 Inhibitors

Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer

From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy

Inhibitors of cyclin-dependent kinases as cancer therapeutics

Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

Inhibitors and PROTACs of CDK2: challenges and opportunities